NCT05300438View on ClinicalTrials.gov

Phase I Study of TSN084 in Patients With Advanced Malignant Tumors.

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

74

Participants

Timeline

Start Date

February 18, 2022

Primary Completion Date

March 31, 2025

Study Completion Date

June 30, 2025

Conditions

Cancer (With or Without Metastasis)

Interventions

DRUG

TSN084

Oral tablets

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

All Listed Sponsors

lead

Tyligand Bioscience (Shanghai) Limited

INDUSTRY